Abstract
Comorbidities between psychiatric diseases and use of traditional substances of abuse are common. Nevertheless, there are few data regarding the use of novel psychoactive substances (NPS) among psychiatric patients. Aim of this multicentre survey is to investigate the consumption of a number of psychoactive substances in a young psychiatric sample. Between December 2013 and September 2015, a questionnaire was administered in 10 Italian psychiatric care facilities to a sample of 671 patients, aged 18-26 (mean age 22.24; SD 2.87). About 8.2% of the sample declared to have used NPS at least once, and 2.2% had consumed NPS in the previous 3 months. The three psychiatric diagnoses most frequently associated with NPS use were bipolar disorder (23.1%), personality disorders (11.8%), and schizophrenia and related disorders (11.6%). In univariate regression analysis, bipolar disorder was positively associated with NPS consumption, an association that did not reach statistical significance in the multivariate analysis. The use of NPS in a young psychiatric population appears to be frequent, and probably still underestimated. Bipolar disorder shows an association with NPS use. Careful and constant monitoring and an accurate evaluation of ...Continue Reading
References
Jan 1, 1997·Harvard Review of Psychiatry·E J Khantzian
Feb 9, 2005·Archives of General Psychiatry·Carol L M CatonW Bella Schanzer
Nov 8, 2005·Journal of Psychopharmacology·Fabrizio SchifanoUNKNOWN Psychonaut 2002 Research Group
Feb 12, 2008·Biological Psychiatry·Mihály HajósBernát Kocsis
May 19, 2009·Addictive Behaviors·G MartinottiM Sarchiapone
Jul 24, 2012·Biological Psychiatry·Mohini RanganathanDeepak Cyril D'Souza
Jul 31, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Paolo DelucaFabrizio Schifano
Jan 31, 2013·Journal of Analytical Toxicology·Laureen J Marinetti, Heather M Antonides
Jul 25, 2013·Human Psychopharmacology·Pierluigi SimonatoFabrizio Schifano
Jul 25, 2013·Human Psychopharmacology·Duccio PapantiTommaso Bonavigo
Mar 29, 2014·Drug Testing and Analysis·Hamilton Morris, Jason Wallach
Jun 7, 2014·Frontiers in Psychiatry·Ralf BrischTomasz Gos
Aug 19, 2014·BioMed Research International·Giovanni MartinottiMassimo di Giannantonio
Feb 7, 2015·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Fabrizio SchifanoJohn M Corkery
Apr 24, 2015·Frontiers in Physiology·Vicent Balanzá-MartínezEduard Vieta
May 8, 2015·BMJ Case Reports·Caroline AndersonDavid Marchevsky
Jul 29, 2015·Human Psychopharmacology·Stefania ChiappiniFabrizio Schifano
Jul 29, 2015·Human Psychopharmacology·Giovanni MartinottiMassimo Di Giannantonio
Jul 29, 2015·Human Psychopharmacology·Laura OrsoliniFabrizio Schifano
Aug 2, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Colin Davidson, Fabrizio Schifano
Oct 28, 2015·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Alison M DinesUNKNOWN Euro-DEN Research Group
May 12, 2016·BMJ Open·Jack L StanleyStephen M Lawrie
Jun 13, 2017·Substance Use & Misuse·Giulia MilanoGilberto Gerra
Citations
Sep 11, 2019·Expert Review of Neurotherapeutics·Laura OrsoliniFabrizio Schifano
Jul 18, 2018·Brain Sciences·Stefania BonaccorsoFabrizio Schifano
May 26, 2018·Therapeutic Advances in Drug Safety·Domenico De BerardisMassimo Di Giannantonio
Jun 13, 2020·Frontiers in Psychiatry·Ornella CorazzaGiuseppe Bersani
Oct 29, 2020·Frontiers in Psychiatry·Giovanni MartinottiMassimo di Giannantonio
Apr 4, 2021·Brain Sciences·Laura Fusar-PoliAndrea Aguglia